August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Augmented reality gains FDA nod, 10k-case milestone in orthopedics, strides in outpatient surgery
- Smart patient selection anchors DISC’s high-acuity spine ASC model
- Postop opioid prescriptions following outpatient surgery see steep, sustained fall
- Study: Bariatric surgery offers cost, survival benefits for cirrhosis patients
- AI monitoring, remote surgery advance
- Rethinking OR routines reduces waste, costs while protecting environment
- Proposed Oregon legislation blocks AI tools from using 'nurse' title
- Communications skills keep surgical patients engaged, informed
- Study: Daytime meals protect heart health in night shift workers
- Borescope inspections reveal widespread contamination in lumened surgical instruments
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement